About MedDEV, Inc.

MedDEV, Inc. is a privately held company incorporated in the state of Washington in 2006. Our company is involved in early stage research and development of small molecule programs and the discovery of new indications and formulations for older medications.

line

 

PROGRAM PIPELINE

Respen-A
•Topical disc for symptoms of impaired communication, impaired social interaction and
disruptive repetitive behaviors.
•US patent pending
•Currently being marketed as a compound prescription

 

MedDEV Drug AM4
•Small molecule delivered via a transdermal disc
•Patent-protected (US and Europe) for use in multiple sclerosis, fibromyalgia,
depression and memory impairment.
•Patent-pending for use in autism spectrum disorders and Alzheimer's Disease.
•Preclinical studies to commence 2010

 

MedDEV Drug EDL1
•Transdermal spray
•Patent-protected in the US for depression and depressive disorders such as bipolar
disorder. European patent pending.
•Patent-pending for use in autism spectrum disorders and schizophrenia.
•Expedited 505(b)(2) regulatory approval pathway
•IND filing imminent; Phase 2 studies to commence.

 



 

 

MedDEV Mission Statement